00
002620.KO Jeil Pharm
- Market cap
- KRW 105B
- P/E
- 12.2x
- P/B
- 0.33x
- ROE
- -1.6%
- Dividend yield
- 0.17%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 002620.KO undervalued?
Graham number002620.KO trades 57.8% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Jeil Pharm fundamental analysis
No fundamental analysis for Jeil Pharm yet.
Jeil Pharm stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Jeil Pharm
Jeil Pharma Holdings Inc manufactures and sells ingredients of drugs, incrementally modified drugs, and generic drugs in South Korea. The company offers active pharmaceutical ingredients in the areas of antibiotics, gastrointestinal, cardiovascular, neuropsychiatry, oncology, endocrinology, urology, antiviral, and antihistamines, as well as patch products. It also provides finished dosage forms in the areas of anti-bacteria and anti-fungal, anti-virus, cardiovascular, endocr…
Full company profileJeil Pharm financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Jeil Pharm annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 617B | 44.4B | 143B | 725B | 762B | 763B | 793B | 804B | 780B | 658B | 630B |
| Gross Profit | 135B | 21.3B | 56.5B | 176B | 191B | 181B | 180B | 215B | 207B | 253B | 249B |
| Operating Income | 9.35B | 292M | 10.9B | 3.32B | 22.5B | -8.97B | -7.55B | 20.9B | -11.2B | 39.0B | -12.6B |
| EBITDA | - | 7.27B | 12.5B | -72.0B | 42.7B | 6.14B | -67.0B | 9.25B | -38.7B | 61.8B | 11.4B |
| Net Income | 7.89B | 519B | 7.07B | -90.7B | 11.4B | -3.48B | -74.6B | -16.2B | -51.2B | 14.6B | -4.89B |
| EPS | - | 139,344 | 461 | -5,906 | 745 | -227 | -4,857 | -1,059 | -3,333 | 953 | -318 |
| Balance Sheet | |||||||||||
| Total Assets | 492B | 198B | 920B | 846B | 887B | 892B | 866B | 880B | 890B | 877B | 892B |
| Total Liabilities | 240B | 27.1B | 331B | 363B | 388B | 392B | 446B | 478B | 453B | 408B | 421B |
| Shareholders' Equity | 249B | 167B | 490B | 393B | 407B | 412B | 338B | 319B | 307B | 319B | 314B |
| Cash & Short-term Investments | 30.0B | 8.75B | 41.1B | 21.2B | 20.2B | 28.6B | 34.8B | 37.0B | 59.8B | 56.2B | 62.7B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 11.4B | 5.92B | -3.43B | 25.2B | -23.7B | 13.4B | -20.8B | -4.42B | 4.54B | 390M | -8.54B |
| Capital Expenditure | 30.3B | 2.94B | 50.2B | 37.7B | 9.81B | 23.7B | 21.4B | 9.84B | 6.86B | 9.33B | 17.3B |
| Free Cash Flow | - | 2.95B | -4.87B | 23.6B | -33.9B | -10.3B | -42.2B | -14.3B | -2.32B | -8.94B | -25.9B |
| Ratios | |||||||||||
| ROE | 3.2% | 311.2% | 1.4% | -23.0% | 2.8% | -0.8% | -22.1% | -5.1% | -16.7% | 4.6% | -1.6% |
| ROA | 1.6% | 262.6% | 0.8% | -10.7% | 1.3% | -0.4% | -8.6% | -1.8% | -5.7% | 1.7% | -0.5% |
| Net Profit Margin | 1.3% | 1,167.4% | 5.0% | -12.5% | 1.5% | -0.5% | -9.4% | -2.0% | -6.6% | 2.2% | -0.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Jeil Pharm dividends
- Dividend yield
- 0.17%
- Forward dividend
- 70.00 KRW
- Payout ratio
- 1.3%
- Ex-dividend date
- Dec 29, 2025
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | KRW 183M | 12 | 1.3% |
| 2024 | KRW 1.13B | 74 | - |
| 2023 | KRW 1.13B | 74 | - |
| 2022 | KRW 1.47B | 96 | - |
| 2021 | KRW 1.59B | 104 | - |
| 2020 | KRW 1.59B | 103 | 13.9% |
| 2019 | KRW 1.52B | 99 | - |
| 2018 | KRW 223M | 15 | 3.2% |
| 2017 | KRW 891M | 239 | 0.2% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 0.292627:1 on Jul 17, 2017.
Who owns Jeil Pharm
- Insiders 82.59%
- Institutions 0.03%
- Public & others 17.38%
- Shares outstanding 15.4M
- Free float 2.16M
Jeil Pharm company profile
- Company name
- Jeil Pharm
- Ticker
- 002620.KO
- ISIN
- KR7002620003
- Exchange
- Korea Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 41
- Fiscal year end
- December
- Address
- 343, Sapyeong-daero, Seoul, South Korea, 06543
- Phone
- 82 2 549 7451
- Website
- jeilpharm.co.kr
About Jeil Pharm
Jeil Pharma Holdings Inc manufactures and sells ingredients of drugs, incrementally modified drugs, and generic drugs in South Korea. The company offers active pharmaceutical ingredients in the areas of antibiotics, gastrointestinal, cardiovascular, neuropsychiatry, oncology, endocrinology, urology, antiviral, and antihistamines, as well as patch products. It also provides finished dosage forms in the areas of anti-bacteria and anti-fungal, anti-virus, cardiovascular, endocrinology, neurology, gastrointestinal, urology, oncology, anti-histamine, rheumatology, respiratory, otolaryngological, heaptic, laxatives, and purgatives. The company exports its products to approximately 40 countries in the Association of Southeast Asian Nations, Central and South America, Africa, etc. The company was founded in 1959 and is headquartered in Seoul, South Korea.
Jeil Pharm management
1- Mr. Seung-Soo HanChairman of The Board and Chief Executive Officer · born 1947